Results 51 to 60 of about 3,108,169 (356)

Curing advanced melanoma by 2025 [PDF]

Current Opinion in Oncology, 2015
To outline the most urgent challenges in the management of advanced melanoma.Considerable progress in targeted and immunotherapy of advanced melanoma has opened a perspective for a cure if all molecular and medical information is integrated in a rational precision treatment algorithm.Bioinformatics and system biology approaches will be needed to deal ...
Dummer, Reinhard, Goldinger, Simone M, Paulitschke, Verena, Levesque, Mitchell P   +3 more
openaire   +2 more sources

Melanoma [PDF]

, 2012
Melanoma is a relatively common neoplasm which is increasing in incidence. Melanoma appears as a variegated irregular maculopapular lesion usually on the skin, but possibly on mucosae, conjunctiva, orbit, nails and oesophagus. They may be black, brown,
Magri, Stephanie, Pace, Keith
core   +1 more source

Metástases cutâneas em melanoma de coróide

Revista Brasileira de Oftalmologia, 2011
Metastasis in choroidal melanoma is frequent on advanced diseases, involving mainly the liver, lungs and central nervous system. We report a case of cutaneous metastasis in choroidal melanoma because is an unusual condition, even in advanced disease.
Fabricio Lopes da Fonseca, Suzana Matayoshi   +1 more
doaj   +1 more source

Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. [PDF]

, 2017
Patients with metastatic uveal melanoma usually die within 1 year of diagnosis, emphasizing an urgent need to develop new treatment strategies. The liver is the most common site of metastasis.
Aplin, Andrew E., Cheng, Hanyin, Chua, Vivian, Davies, Michael A., Kageyama, Ken, Liao, Connie, Purwin, Timothy J., Sato, Takami, Terai, Mizue   +8 more
core   +2 more sources

Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma.

JAMA Oncology, 2022
Importance Management of checkpoint inhibitor-induced immune-related adverse events (irAEs) is primarily based on expert opinion. Recent studies have suggested detrimental effects of anti-tumor necrosis factor on checkpoint-inhibitor efficacy ...
O. V. van Not, R. Verheijden, A. van den Eertwegh, J. Haanen, M. Aarts, F. van den Berkmortel, C. Blank, M. Boers-Sonderen, J. D. de Groot, G. Hospers, A. M. Kamphuis, E. Kapiteijn, A. May, M. D. de Meza, D. Piersma, R. V. van Rijn, Marion A. Stevense-den Boer, A. V. D. van der Veldt, G. Vreugdenhil, W. Blokx, M. Wouters, K. Suijkerbuijk   +21 more
semanticscholar   +1 more source

Advances in immunotherapy for melanoma [PDF]

BMC Medicine, 2016
In recent years, the introduction and Federal Drug Administration approval of immune checkpoint inhibitor antibodies has dramatically improved the clinical outcomes for patients with advanced melanoma. These antagonist monoclonal antibodies are capable of unleashing dormant or exhausted antitumor immunity, which has led to durable complete and partial ...
Redman, Jason M., Gibney, Geoffrey T., Atkins, Michael B.   +2 more
openaire   +2 more sources

Fallen dogmas – recent advances in locoregionally advanced melanoma [PDF]

Polish Archives of Internal Medicine, 2021
Last decade brought new achievements in the melanoma research, which resulted in an important changes in the clinical management of stage III melanoma. The article summarizes recent updates with particular focus on practical aspects. Results from surgical studies, Multicenter Selective Lymphadenectomy Trial II (MSLT-II) and German Dermatologic ...
Wojciech M, Wysocki, Aleksandra, Grela-Wojewoda, Michał, Jankowski   +2 more
openaire   +2 more sources

Gastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic review

Melanoma Management, 2018
Introduction: Immunotherapies, including checkpoint inhibitors (CIs) such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) inhibitors, are revolutionizing the treatment of advanced melanoma.
Elizabeth S Mearns, Jill A Bell, Aaron Galaznik, Stefanie M Puglielli, Allie B Cichewicz, Talia Boulanger, Ignacio Garcia-Ribas   +6 more
doaj   +1 more source

Severe Demyelinating Neuropathy in an Advanced Melanoma Patient Treated with Nivolumab plus Ipilimumab Combined Therapy

Case Reports in Oncology, 2020
Immune checkpoint inhibitors (ICIs) significantly prolong survival in patients with metastatic melanoma but can lead to serious immune-related adverse events.
Yumi Kambayashi, Taku Fujimura, Hiroshi Kuroda, Atsushi Otsuka, Hiroyuki Irie, Setsuya Aiba   +5 more
doaj   +1 more source

Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression‐free survival based on reconstructed individual patient data

Cancer Medicine, 2023
Background In patients with advanced melanoma, immune‐checkpoint inhibitors (ICIs) represent the mainstay for first line treatment. Recently, relatlimab+nivolumab was proposed as a new combination therapy. This review was aimed at summarizing the current
Andrea Ossato, Vera Damuzzo, Paolo Baldo, Daniele Mengato, Marco Chiumente, Andrea Messori   +5 more
doaj   +1 more source